News

BerGenBio ASA – Key information related to the rights issue

Announcement of fully underwritten rights issue

BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

BerGenBio ASA – Minutes from the annual general meeting 2025

BerGenBio ASA: Update on Strategic Review Process and Status of Activities

BerGenBio ASA: Notice of Annual General Meeting

BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar

BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

BerGenBio announces advancement of its strategic review